"Multiple Sclerosis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903)
Descriptor ID |
D009103
|
MeSH Number(s) |
C10.114.375.500 C10.314.350.500 C20.111.258.250.500
|
Concept/Terms |
Multiple Sclerosis- Multiple Sclerosis
- Sclerosis, Multiple
- Sclerosis, Disseminated
- Disseminated Sclerosis
- MS (Multiple Sclerosis)
|
Below are MeSH descriptors whose meaning is more general than "Multiple Sclerosis".
Below are MeSH descriptors whose meaning is more specific than "Multiple Sclerosis".
This graph shows the total number of publications written about "Multiple Sclerosis" by people in this website by year, and whether "Multiple Sclerosis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1993 | 6 | 0 | 6 |
1994 | 4 | 0 | 4 |
1995 | 4 | 1 | 5 |
1996 | 9 | 0 | 9 |
1997 | 2 | 0 | 2 |
1998 | 7 | 2 | 9 |
1999 | 3 | 0 | 3 |
2000 | 2 | 0 | 2 |
2002 | 4 | 0 | 4 |
2003 | 2 | 0 | 2 |
2004 | 3 | 0 | 3 |
2005 | 3 | 0 | 3 |
2006 | 2 | 0 | 2 |
2007 | 4 | 0 | 4 |
2008 | 2 | 1 | 3 |
2009 | 4 | 0 | 4 |
2010 | 4 | 2 | 6 |
2011 | 6 | 1 | 7 |
2012 | 7 | 1 | 8 |
2013 | 7 | 0 | 7 |
2014 | 4 | 0 | 4 |
2015 | 2 | 0 | 2 |
2016 | 2 | 0 | 2 |
2017 | 4 | 0 | 4 |
2018 | 4 | 0 | 4 |
2019 | 4 | 0 | 4 |
2020 | 3 | 1 | 4 |
2021 | 7 | 0 | 7 |
2022 | 3 | 0 | 3 |
2023 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Multiple Sclerosis" by people in Profiles.
-
Prolonged Interferon-Stimulated Gene and Protein Signatures in Multiple Sclerosis Induced by PEGylated IFN-?-1a Compared to Non-PEGylated IFN-?-1a. J Interferon Cytokine Res. 2023 03; 43(3):108-120.
-
Effectiveness of ocrelizumab on clinical and MRI outcome measures in multiple sclerosis across black and white cohorts: A single-center retrospective study. Mult Scler Relat Disord. 2023 Mar; 71:104523.
-
T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy. Mult Scler. 2023 05; 29(6):648-656.
-
Analysis of the extent of limbic system changes in multiple sclerosis using FreeSurfer and voxel-based morphometry approaches. PLoS One. 2022; 17(9):e0274778.
-
Sex differences in the genetic architecture of cognitive resilience to Alzheimer's disease. Brain. 2022 07 29; 145(7):2541-2554.
-
Medications for Multiple Sclerosis and Risk of Malignancy: What Next? Neurotherapeutics. 2021 07; 18(3):1650-1653.
-
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial. Mult Scler. 2022 04; 28(5):790-800.
-
Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs. 2021 07; 35(7):743-767.
-
Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2021 Jun; 51:102935.
-
Anti-CD20 therapy corrects a CD8 regulatory T cell deficit in multiple sclerosis. Mult Scler. 2021 12; 27(14):2170-2179.